Sanofi has announced that its drug Sarclisa (isatuximab) has received approval from the European Commission for the treatment of newly diagnosed multiple myeloma patients. This approval expands the therapeutic options for patients across Europe battling this challenging blood cancer.
Sarclisa is a CD38-directed monoclonal antibody that works by targeting specific proteins on myeloma cells, helping to eliminate them. The approval covers its use in combination with standard therapies, enhancing efficacy in frontline treatment.
This milestone reflects Sanofi’s ongoing commitment to innovating cancer care and providing patients with effective treatment solutions. With multiple myeloma affecting thousands across Europe, the availability of Sarclisa offers new hope for improved outcomes.
Sanofi continues to advance research in hematology and oncology, aiming to improve survival rates and quality of life for patients worldwide.
